Connected With Latham
Business & Finance
About
In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.
Episodes
- Episode 116 – Drug Pricing and Market Access: CMS Update With Rujul Desai
The Trump administration has advanced many policy initiatives in the drug pricing and market access area, and CMS —the Centers for Medicare & Medicaid Services — is the agency at the heart of many of these efforts. Rujul Desai, Senior Coun…
- Episode 115 – Drug Pricing and Market Access: Highlights From Recent CMS and AHLA Conferences
Washington, D.C. partner Chris Schott , and associates Danny Machado and Evan Rothkoff , share observations and insights from the recent Centers for Medicare & Medicaid Services (CMS) Quality Conference and the American Health Law Associat…
- Episode 114 – The Growth Rocketship: Using AI and Human Expertise to Build Tomorrow's Leading Brands With A-Frame
A-Frame Brands identifies emerging signals in culture, consumer behavior, and category white space — then moves fast to bring the right products to shelf. They work two ways: co-creating private-label and exclusive product lines with the w…
- Episode 113 – Helping Holocaust Survivors
Over two decades, more than 350 Latham lawyers have taken on Holocaust reparations matters, helping Holocaust survivors apply for pensions for work performed in Nazi-controlled ghettos during World War II. In this episode of Connected With…
- Episode 112 – The Growth Rocketship: Navigating the Institutional Evolution of the Blockchain World With ParaFi
ParaFi Capital is an alternative asset management and technology firm focused on blockchain and digital assets. Founded in 2018, the firm was among the earliest institutional investors in the blockchain industry and has evolved into a trus…
- Episode 111 – The Growth Rocketship: The Future of Rewards-Based Advertising With Fetch
Founded in 2013, Fetch is a daily rewards destination for consumers and brands, turning everyday actions like shopping, dining out, and playing games into tangible value for consumers while delivering measurable advertising for consumer, r…
- Episode 110 – Spotlight on US State Healthcare Transaction Review Laws
States continue to expand their review of healthcare transactions involving private equity, real estate investment trusts, management services organizations, and other investors. Join Washington, D.C. counsel Nicole Liffrig Molife , Los An…
- Episode 109 – Drug Pricing and Market Access: Key Takeaways From 2025 and Outlook for 2026
The drug pricing and market access policy space saw a lot of change in 2025, and the pace is not slowing down. In this episode of Connected With Latham, pharmaceutical industry veteran Sabrina Aery , founder of Aery Policy and Access Partn…
- Episode 108 – UK FinReg Focus Areas in 2026
In this episode of Connected with Latham, complementing Latham's " 10 Key Focus Areas for UK-Regulated Financial Services Firms in 2026" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Critchley discuss the key trend…
- Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's aggressive pricing policies. In this episode of Connected With Latham, Mike Domanico, a pha…
- Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway
Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "plausible mechanism" pathway for personalized therapies, and new draft guidance aimed at st…
- Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function. They can also help uncovering strategic benefits and opportunities. In this episode of Connected Wi…
- Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards
The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN…
- Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2025. In this episode of Connected…
- Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services
In this episode of Connected With Latham , London partner Fiona Maclean , Paris partner Jean-Luc Juhan , and London counsel Alain Traill discuss significant new switching requirements due to take effect for data processing services under t…
- Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity
In this episode of Connected With Latham , London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means for data privacy and cybersecurity practices. This podcast is provided as a service of L…
- Episode 100 – The Leeds Reforms: Implications for UK Financial Services
In this episode of Connected with Latham , London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services sector, and key takeaways for financial services firms. This podcast is provided as a serv…
- Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for the Pricing and Contracting USA Conference. In this episode of Connected With Latham , Al…
- Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufactur…
- Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and accelerated approval of generics and biosimilars. In this episode of Connected With Latham…
- Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech
Founded in 2015, Shield AI uses technology and intelligence systems to protect service members and civilians. The venture-backed unicorn's flagship autonomy software, Hivemind, powers aircraft, drones, and other platforms to reliably suppo…
- Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
The initial months of the Trump administration have been marked by a flurry of executive orders and significant activity by the Department of Government Efficiency (DOGE). The US Food and Drug Administration is a key target of these effort…
- Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Conference. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott an…
- Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the EU market and impacts a broad range of third-party providers of technology-related service…
- Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
In this episode of Connected with Latham, the final of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Crit…
- Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
In this episode of Connected with Latham, the second of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Cri…
- Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
In this episode of Connected with Latham , the first of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services Firms in 2025" report, London partners Rob Moulton and Nicola Higgs and counsel Becky Cri…
- Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?
In this episode of Connected With Latham , Haim Zaltzman , Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio 's Co-Founder and Chief Executive Officer Neil Kumar and Chief Financial Officer Brian…
- Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
FDA enforcement activities range from administrative actions like conducting establishment inspections and issuing warning letters to judicial enforcement through the Department of Justice, which can take the shape of civil or criminal act…
- Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?
The Centers for Medicare & Medicaid Services (CMS) recently published its final rule to implement the Medicaid Services Investment and Accountability Act of 2019 (MSIAA). The final rule significantly deviates from the agency's 2023 proposa…
- Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this episode of Connected with Latham, Washington, D.C. associate Danny Machado interviews part…
- Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the long-standing Chevron doctrine, will likely impact how federal agencies interpret ambi…
- Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US
In this episode of Connected with Latham , we explore the remarkable story of Shabir Kabiri, an Afghan refugee who secured asylum in the United States with the help of a Latham pro bono team. Shabir shares his harrowing journey, his time a…
- Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
The US healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation Reduction Act (IRA). One key stakeholder group affected by the IRA drug price negotiat…
- Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Current developments grabbed much of the spotlight when key industry stakeholders met in New Orleans for the Pricing and Contracting USA Conference. In this episode of Connected With Latham , Washington, D.C. partner Chris Schott and assoc…
- Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
The Centers for Medicare and Medicaid Services (CMS) recently updated its portal for Average Sales Price (ASP) reporting under Medicare Part B. Data collection portals are also essential for manufacturer compliance with the Inflation Reduc…
- Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
As the energy tech sector continues to mature, venture capital offers an increasingly a viable path to growth as emerging energy tech companies seek to disrupt the energy space, often following a fundraising and growth trajectory similar t…
- Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Latham's recently released 2023 Pro Bono Annual Review highlights our public service initiatives around the world, including our ongoing relationship with Trees for Life . This conservation charity is dedicated to rewilding the Scottish Hi…
- Episode 78 – UK FinReg Focus Areas in 2024: ESG
Following an array of ESG-focused regulation and escalating concerns of greenwashing risks in 2023, the year ahead looks to deliver significant industry developments at a rapid pace. In the UK, the FCA's Sustainability Disclosure Requireme…
- Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
In 2023, the FCA brought more charges for fraud offences against individuals than any other year in the regulator's history, and secured several convictions related to fraudulent investment schemes. Yet while the FCA has signaled that econ…
- Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
The UK's announcement of the Edinburgh Reforms in 2022 made clear the government's intention to chart its own course in rulemaking for the UK financial services sector, and no longer prioritise equivalence with EU legislation. The UK is cu…
- Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Two new Joint Executive Directors of Enforcement and Market Oversight appointed by the FCA in 2023 will settle into their roles over the year ahead. Following a period of enforcement defined by increased investigations and a willingness to…
- Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
With the UK financial services regulators due to publish Policy Statements to their consultations on diversity and inclusion (D&I) this year, conduct and culture remain high on the regulators' agenda and connect closely to their other regu…
- Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
The coming year looks poised to act as a pivotal junction for the UK financial services regulators in deciding how to approach the regulation of artificial intelligence (AI), as the financial services industry sees the continued expansion…
- Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Since the announcement of the Edinburgh Reforms in 2022, the UK government has made progress on an assortment of measures spanning financial services regulation, with more developments expected in 2024. Though tabled initially as an ambiti…
- Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
The pressure and uncertainty of 2023 will likely continue for drug manufacturers in 2024, with the election cycle bringing added scrutiny. At the federal level, continuing implementation of the Inflation Reduction Act, including publicatio…
- Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
The UK's decision to scrap compulsory research unbundling, following the final recommendations of the Investment Research Review, marked one of the most striking developments for financial services firms in 2023. Permitting rebundling acro…
- Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
As part of the FCA's continued focus on retail markets, updates to several key regimes are due to progress over the next year. In addition to further implementation of the FCA's Consumer Duty, the government plans to present detailed propo…
- Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
The National Institute of Standards and Technology (NIST) recently published a draft guidance framework for considering the exercise of march-in rights. Under the Bayh-Dole Act, government agencies can "march in" on patents resulting from…
- Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
Cyberattacks targeting well-resourced businesses, especially those with institutional backing, financial support, and deep insurance coverage, have become increasingly prevalent. PE portfolio companies in particular find themselves in the…